WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bristol-Myers Squibb

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

www.bms.com.

Bristol-Myers Squibb RSS Channel

Filters
List of articles in category Bristol-Myers Squibb
Title Published Date
Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ real-world data program grows to sample size of nearly one million lives worldwide 20 August 2018
Bristol-Myers Squibb announces worldwide collaboration with Janssen to develop and commercialize next-generation cardiovascular therapy 16 April 2018
Bristol-Myers Squibb and Harvard announce new fibrosis research collaboration 12 April 2018
Bristol-Myers Squibb's Opdivo® (nivolumab) now the first and only FDA-approved PD-1 inhibitor to offer every four-week dosing 07 March 2018
Bristol-Myers Squibb announces expansion of the International Immuno-Oncology Network (II-ON) with addition of Yale Cancer Center 01 March 2018
Bristol-Myers Squibb and Nektar Therapeutics announce global development & commercialization collaboration for Nektar's CD122-biased agonist, NKTR-214 15 February 2018
Bristol-Myers Squibb and Pfizer Alliance urge people to 'Tune in to AFib, Take Note of Stroke Risk' 05 December 2017
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Neutrolis, Remora Therapeutics 28 November 2017
BMS-Pfizer Alliance to unveil real-world data analyses - cost, safety and comparative effectiveness findings associated with oral anticoagulants in non-valvular atrial fibrillation 10 November 2017
FDA accepts Bristol-Myers Squibb's application for Opdivo (nivolumab) in patients with resected high-risk advanced melanoma and grants priority review 17 October 2017
Caregivers wish liver cancer received greater public awareness in the U.S., new survey reveals 04 October 2017
AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors 22 September 2017
Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for ENHANZE technology 14 September 2017
Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics 07 September 2017
Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Stand Up To Cancer 06 September 2017
Bristol-Myers Squibb announces topline results from CheckMate -214 15 August 2017
Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity 03 August 2017
Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration 31 July 2017
U.S. Food and Drug Administration expands approval of Yervoy® (ipilimumab) to include pediatric patients 12 years and older with unresectable or metastatic melanoma 24 July 2017
Bristol-Myers Squibb to sell manufacturing facility in Swords, Ireland to SK Biotek Co., Ltd. 16 June 2017
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
  • AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge

Research & Development

  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer
  • Engineered bacteria find tumors, then alert the authorities
  • First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Bristol-Myers Squibb

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.